Nutrafol Co-Founder Tsetis Launches Family Office to Invest in Social Good
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- New Investment Direction: After selling his stake in Nutrafol, Tsetis launched the family office Great Things, aiming to use investment profits to support charities focused on mental health and crisis response, reflecting his commitment to social responsibility.
- Early Investment Strategy: Since Nutrafol's Series B funding, Tsetis has actively engaged in early-stage startup investing, with a portfolio that includes AI-driven health tech companies, showcasing his dual focus on innovation and social impact.
- Family Office Development: Great Things currently employs six full-time staff, with Tsetis's wife advising on philanthropy, indicating his determination to promote socially responsible investing and the importance of family involvement.
- Wealth and Responsibility: Tsetis emphasizes that wealth transfer should not solely be about accumulation but should integrate social responsibility, encouraging other investors to consider giving back as a core part of their investment strategies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on UL
Wall Street analysts forecast UL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UL is 68.37 USD with a low forecast of 60.10 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 66.530
Low
60.10
Averages
68.37
High
74.00
Current: 66.530
Low
60.10
Averages
68.37
High
74.00
About UL
Unilever PLC is a United Kingdom-based fast-moving consumer goods (FMCG) company. The Company operates through five segments: Beauty & Wellbeing, Personal Care, Home Care, Foods, and Ice Cream. The Beauty & Wellbeing segment sells hair care (shampoo, conditioner, styling), skin care (face, hand and body moisturizers) and includes Prestige Beauty and Health & Wellbeing. The Personal Care segment sells skin cleansing (soap, shower), deodorant and oral care (toothpaste, toothbrush, mouthwash) products. The Home Care segment sells fabric care (washing powders and liquids, rinse conditioners) and a range of cleaning products. The Foods segment sells cooking aids & mini-meals (soups, bouillons, seasonings), condiments (mayonnaise, ketchup) and Unilever Food Solutions. The Ice Cream segment includes ice cream products. It offers K18, which is a biotech hair care brand. Its subsidiaries include Unilever de Argentina S.A., Unilever Australia Limited, Unilever Canada Inc., and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SEMICAB ANNOUNCES INITIAL CONTRACT EXPANSION FOR 2026 WITH UNILEVER INDIA
- Contract Announcement: Semicab Secures its first contract for the expansion of 2026 with Unilever in India.
- Strategic Partnership: The collaboration aims to enhance operational capabilities and support Unilever's growth in the region.
- Market Impact: This partnership is expected to strengthen Semicab's position in the Indian market and contribute to its long-term growth strategy.
- Future Prospects: The contract signifies a commitment to innovation and sustainability in the supply chain for both companies.
Continue Reading
Oakmark International Fund Underperforms in Q4 but Outperforms for Year
- Quarterly Performance Review: The Oakmark International Fund underperformed the MSCI World ex USA Index in Q4, yet it outperformed the benchmark for the calendar year and since inception, indicating potential for long-term investment growth.
- New Investment Activity: In Q4, the fund made new purchases in AstraZeneca (AZN), IMCD NV (IMCDY), Sanofi (SNY), Symrise (SYIEF), and Unilever (UL), reflecting its ongoing focus on the biopharmaceutical and consumer goods sectors.
- Final Sales Overview: The fund completed final sales of Exor (EXXRF), Komatsu (KMTUY), Mercedes-Benz Group (MBGAF), Novartis (NVS), SKF Cl B Sandvik (SDVKY), Schroders (SHNWF), and Worldline (WWLNF), showcasing its dynamic portfolio adjustments.
- Industry Conference Participation: The fund participated in the 44th Annual J.P. Morgan Healthcare Conference, where AstraZeneca and Sanofi presented, highlighting their strategic positioning and market outlook in the healthcare sector.
Continue Reading